Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890407 | 0.95 | MAPK1 (0.56) | MAPK1HIF1ATHRBTDP1SLC6A3 | |
| SCHEMBL20192056 | 0.95 | MAPK1 (0.56) | MAPK1HIF1ATHRBTDP1SLC6A3 | |
| SCHEMBL16142139 | 0.92 | MAPK1 (0.54) | MAPK1HIF1ATHRBTDP1SLC6A3 | |
| SCHEMBL21164111 | 0.90 | MAPK1 (0.51) | MAPK1HIF1ATHRBTDP1SLC6A3 | |
| SCHEMBL21318094 | 0.89 | ESR1 (0.51) | MAPK1HIF1ATHRBTDP1CYP2D6 | |
| SCHEMBL30485505 | 0.88 | ALDH1A1 (0.65) | MAPK1HIF1ATHRBTDP1SLC6A3 | |
| SCHEMBL235921 | 0.87 | MAPK1 (0.81) | MAPK1HIF1ATDP1SLC6A3CYP2D6 | |
| SCHEMBL13946535 | 0.87 | MAPK1 (0.61) | MAPK1HIF1ATHRBTDP1SLC6A3 | |
| SCHEMBL69510 | 0.87 | MAPK1 (0.56) | MAPK1HIF1ATHRBTDP1SLC6A3 | |
| SCHEMBL12009414 | 0.87 | MAPK1 (0.56) | MAPK1HIF1ATHRBTDP1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319390-B2 | Poly(ethylene glycol) methacrylate microgels, preparation method and uses | LVMH RECHERCHE (FR) | 2022-05-03 | — | — | US | claimed |
| US-20250333476-A1 | ENGINEERED CD47 PROTEINS AND USES THEREOF | SANA BIOTECHNOLOGY INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250230470-A1 | SAFETY SWITCHES TO CONTROL IN VITRO AND IN VIVO PROLIFERATION OF CELL THERAPY PRODUCTS | SANA BIOTECHNOLOGY, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025151838-A1 | SAFETY SWITCHES TO CONTROL IN VITRO AND IN VIVO PROLIFERATION OF CELL THERAPY PRODUCTS | SANA BIOTECHNOLOGY, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12351667-B2 | Separator for electrochemical energy accumulators and converters | CARL FREUDENBERG KG (DE) | 2025-07-08 | — | — | US | disclosed |
| US-20250127820-A1 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS | SANA BIOTECHNOLOGY, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025054202-A1 | METHOD OF SCREENING A SAMPLE COMPRISING A TRANSGENE WITH A UNIQUE BARCODE | SANA BIOTECHNOLOGY, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-12242188-B2 | Photosensitive resin composition for imprinting, cured article and optical element | ECHEM SOLUTIONS CORP. (TW) | 2025-03-04 | — | — | US | disclosed |
| CN-119372151-A | Cells differentiated from immune engineered pluripotent cells | 加利福尼亚大学董事会 | 2025-01-28 | — | — | CN | disclosed |
| EP-3975927-B1 | MUCOADHESIVE MICROGEL COMPOSITIONS AND METHODS FOR USING THE SAME | UNIV LELAND STANFORD JUNIOR (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2009056955-A1 | AMINE-BEARING PHOSPHOLIPIDS (ABPS), THEIR SYNTHESIS AND USE | UNIVERSITY OF BASEL (CH) | 2009-05-07 | — | — | WO | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-7427394-B2 | Delivering labile agents; buffering effect; transfecting nucleic acids; nontoxic | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427394-B2 | Delivering labile agents; buffering effect; transfecting nucleic acids; nontoxic | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-23 | — | — | US | disclosed |
| WO-2008109105-A2 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH SIRNA | FLAGSHIP VENTURES (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080145338-A1 | Acrylate-terminated poly(beta-amino esters); high throughput assay; biocompatability | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-19 | — | — | US | disclosed |
| US-20080145338-A1 | Acrylate-terminated poly(beta-amino esters); high throughput assay; biocompatability | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-19 | — | — | US | disclosed |
| WO-2008011561-A2 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007143659-A2 | CROSSLINKED, DEGRADABLE POLYMERS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145338-A1 | Acrylate-terminated poly(beta-amino esters); high throughput assay; biocompatability | ACP1, ILK, BCAT2 | MAPK1 2083/4885HIF1A 2413/4885THRB 867/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | MAPK1 4777/4885HIF1A 2383/4885THRB 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.